Dublin, Ireland, September 25, 2015 – DS Biopharma, a privately held biopharmaceutical company, today announced the appointment of Leopoldo Zambeletti as a Non-Executive Director to the […]
Dublin, Ireland, 14 May, 2015: DS Biopharma (DS), a privately held drug discovery and development company, today announced that it will present at the UBS Global […]
DS Biopharma (DS) presents late-breaking news abstract on DS107 at the American Association of Dermatology (AAD) Annual Meeting; “The effective and safe use of DS107 cream […]
DS Biopharma finds that orally administered DGLA distributes well to the skin resulting in high dermal bioavailability. DS Biopharma, a privately held biopharmaceutical company, today announced […]
DS Biopharma, a privately held biopharmaceutical company, have announced positive Phase II results for DS107E (DGLA cream), as a topical treatment for atopic dermatitis. This study was a […]
DS Biopharma, a privately held biopharmaceutical company, today announced two non-executive director appointments to the company’s Board, Dr. John Devane and Mr. Alan Cooke. “We are […]
DS Biopharma Announces Notification of Patent Allowance for U.S. Application 13/318,290, Protecting its Lead Candidate and Next Generation Compounds Exclusivity for Topical Compositions of DS Biopharma‘ […]
DS Biopharma Announces Notification of Patent Allowance for U.S. Application 13/478,982 Protecting DS107F, a Next Generation Acne Therapy Select Preclinical Data to be Presented at the […]
DS Biopharma Completes €8M Financing to Develop Next-Generation Dermatological Therapies Provides sufficient capital to complete the DS107 Phase II programs and expand its portfolio Dublin, Ireland, […]
DS Biopharma and Equateq Ltd today announced a strategic agreement that provides DS Biopharma with synthetic lipids for the next phase of its DS107 clinical development […]
DS Biopharma today announced that it has signed an assignment agreement with Equateq to acquire patent application PCT/GB2010/000844. The terms of the agreement were undisclosed. The […]